Answers are grounded in this paper and cite their sources.
Sulfamethoxazole and other sulfa drugs are moderately potent inhibitors of Escherichia coli dihydrofolate reductase. They also significantly potentiate the inhibition of this enzyme by trimethoprim. The molecular basis for inhibition potentiation is the simultaneous binding of trimethoprim and sulfa by the enzyme. This potentiation may explain the synergism observed when these drugs are used in antibacterial chemotherapy.
No takes yet. Share an insight, caveat, or question.
Martin Poe (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: